Rosemont's $56M Aytu bid shows buyers paying for growing launches, not pipelines
A $2.70-per-share tender for Aytu, with EXXUA at $4.9M of $14.8M quarterly revenue, sits among a run of small-cap deals and strategic reviews across the sector.
What happened
Aytu BioPharma has agreed to be acquired by Rosemont Pharmaceuticals Holdings for about $56M. Rosemont will launch a cash tender offer at $2.70 per share. The announcement came with Aytu's first-quarter fiscal 2027 results: revenue of $14.8M, of which EXXUA contributed $4.9M, roughly one-third of the total.
The material does not give the tender's minimum-acceptance threshold, expected closing date, financing, or any premium to Aytu's prior share price. Those terms will determine how the deal is judged, and we do not speculate on them here.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Sources
- Aytu BioPharma to be acquired by Rosemont for about $56M as EXXUA sales grow Aytu Biopharma, Inc · 16 Nov 2026
- Gedeon Richter to acquire Mayne Pharma in AUD 604 million cash deal Gedeon Richter · 16 Nov 2026
- Merck KGaA to acquire Rapid Micro Biosystems in $0.75-per-share cash tender offer Rapid Micro Biosystems, Inc. · 16 Nov 2026
- ENDRA reports Q3 net loss of $1.5m as Noble Africa merger awaits closing conditions ENDRA Life Sciences Inc. · 16 Nov 2026
- Jasper Therapeutics completes IgAN cohort enrolment as Kira deal closes and cash reaches $135.3M Jasper Therapeutics, Inc. · 16 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Vir's Follow-On Tests Whether Open Equity Windows Favor Platform Stories Over Small-Cap Fixes
Vir Biotechnology's unpriced offering lands the same week as a $225M Windward IPO and a string of warrant-laden small-cap raises, showing how differently capital is available across biotech.
Tenon Medical's $15.6M raise clears convertibles and Nasdaq risk, but not the funding question
The SI joint fusion maker used a quarter of financing to repay senior notes early and regain listing compliance. Peers' Q3 raises show how different the small-cap capital market has become.
IM Cannabis funds a shrinking business with converts while peers raise on scale and strategics
IM Cannabis's nine-month loss and shareholders' deficit sit against a week of financings in which strategic capital and clinical catalysts, not survival needs, set the terms.